Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Receives $16.07 Average Price Target from Brokerages

Shares of Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) have been given an average rating of “Moderate Buy” by the seven research firms that are currently covering the stock, MarketBeat reports. Three investment analysts have rated the stock with a hold recommendation and four have given a buy recommendation to the company. The average twelve-month price objective among brokerages that have covered the stock in the last year is $16.07.

MRNS has been the topic of several recent research reports. HC Wainwright reiterated a “buy” rating and set a $27.00 target price on shares of Marinus Pharmaceuticals in a research report on Tuesday, April 16th. Truist Financial decreased their target price on shares of Marinus Pharmaceuticals from $25.00 to $10.00 and set a “buy” rating on the stock in a research report on Wednesday, April 17th. StockNews.com lowered shares of Marinus Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Wednesday, March 6th. Oppenheimer reiterated a “market perform” rating and set a $9.00 target price on shares of Marinus Pharmaceuticals in a research report on Thursday, March 7th. Finally, Cantor Fitzgerald reiterated an “overweight” rating and set a $28.00 target price on shares of Marinus Pharmaceuticals in a research report on Wednesday, April 10th.

Marinus Pharmaceuticals Stock Performance

Shares of MRNS opened at $1.51 on Friday. The company’s fifty day moving average is $6.69 and its 200-day moving average is $7.96. Marinus Pharmaceuticals has a 12 month low of $1.11 and a 12 month high of $11.26. The firm has a market cap of $82.94 million, a price-to-earnings ratio of -0.57 and a beta of 1.14. The company has a quick ratio of 4.01, a current ratio of 4.07 and a debt-to-equity ratio of 5.68.

Marinus Pharmaceuticals (NASDAQ:MRNS) last announced its quarterly earnings results on Tuesday, March 5th. The biopharmaceutical company reported ($0.74) EPS for the quarter, missing the consensus estimate of ($0.64) by ($0.10). Marinus Pharmaceuticals had a negative return on equity of 269.75% and a negative net margin of 456.31%. The business had revenue of $7.19 million for the quarter, compared to analyst estimates of $7.78 million. During the same quarter last year, the company earned ($0.76) EPS. Equities analysts expect that Marinus Pharmaceuticals will post -2.23 EPS for the current fiscal year.

Institutional Trading of Marinus Pharmaceuticals

Hedge funds have recently added to or reduced their stakes in the business. BluePath Capital Management LLC bought a new position in Marinus Pharmaceuticals during the 3rd quarter worth about $38,000. China Universal Asset Management Co. Ltd. increased its holdings in Marinus Pharmaceuticals by 383.7% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 6,307 shares of the biopharmaceutical company’s stock worth $69,000 after purchasing an additional 5,003 shares in the last quarter. SG Americas Securities LLC bought a new position in shares of Marinus Pharmaceuticals in the 4th quarter valued at about $134,000. Sherbrooke Park Advisers LLC bought a new position in shares of Marinus Pharmaceuticals in the 3rd quarter valued at about $141,000. Finally, Acuta Capital Partners LLC bought a new position in shares of Marinus Pharmaceuticals in the 3rd quarter valued at about $157,000. Institutional investors and hedge funds own 98.80% of the company’s stock.

About Marinus Pharmaceuticals

Marinus Pharmaceuticals, Inc, a pharmaceutical company, focuses on development and commercialization of therapeutic products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY (ganaxolone), an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings.